Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyell Immunopharma, Inc.

9.69
+0.26002.76%
Post-market: 9.690.00000.00%15:47 EDT
Volume:35.84K
Turnover:341.39K
Market Cap:143.49M
PE:-0.39
High:9.81
Open:9.37
Low:9.37
Close:9.43
Loading ...
Oct 24, 2024

Major Issues Report

Form 8-K - Current report
Aug 08, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2024

Major Issues Report

Form 8-K - Current report
Jun 26, 2024

Major Issues Report

Form 8-K - Current report
Jun 14, 2024

Major Issues Report

Form 8-K - Current report
May 06, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 06, 2024

Major Issues Report

Form 8-K - Current report
May 02, 2024

Correspondence

Form CORRESP - Correspondence
Feb 29, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Feb 29, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 28, 2024

Major Issues Report

Form 8-K - Current report
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Nov 21, 2023

Major Issues Report

Form 8-K - Current report
Nov 08, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 08, 2023

Major Issues Report

Form 8-K - Current report
Sep 11, 2023

Major Issues Report

Form 8-K - Current report
Aug 15, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 15, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 15, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities